Molecule Details
| InChIKey | DAYKLWSKQJBGCS-NRFANRHFSA-N |
|---|---|
| Canonical SMILES | CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.57 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB08915 |
|---|---|
| Drug Name | Aleglitazar |
| CAS Number | 475479-34-6 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at ... |
Categories: Sulfur Compounds
Cross-references: BindingDB: 50277897 CHEMBL519504 ChemSpider: 8450255 D08845 PDB: RO7 PubChem:10274777 PubChem:175427152 Wikipedia: Aleglitazar ZINC: ZINC000049573657